PSG
7.4.2021 09:02:09 CEST | Business Wire | Press release
Imaweb, a leading independent developer and provider of automotive and dealership software solutions in Europe, today announced the acquisition of Stieger, a leading dealership software solutions provider in Switzerland and Austria. Imaweb is backed by PSG, a growth equity firm that focuses on partnering with middle-market software and technology-enabled service companies.
Headquartered in Staad, Switzerland, Stieger simplifies client processes and improves efficiency for original equipment manufacturers (“OEMs”) and dealerships through its innovative software solutions. Founded in 1982, the company currently employs around 60 people across six locations in Switzerland, Austria and Slovakia. Stieger clients include Swiss and Austrian franchise dealers across a number of OEM brands, such as Volkswagen, Audi, Renault, Ford, Toyota, Peugeot, Volvo, Mercedes and Citroën.
The acquisition of Stieger will strengthen Imaweb’s presence in DACH, the largest automotive market in Europe, and Stieger’s market leading positions in Switzerland and Austria will complement Imaweb’s existing presence in Germany. Furthermore, Stieger’s product offering is additive to Imaweb’s digital software solutions which support the digitalisation of the overall customer journey for dealerships and OEMs. Following the transaction, Stieger’s CEO and Founder Eugen Stieger will retire from the business.
“We are delighted to onboard Stieger as part of Imaweb,” said Patrick Prajs, CEO of Imaweb. “We believe that the company’s innovative technology will bring an added edge to our existing offering to OEMs and dealerships across Europe.”
Julian Ciccale, Co-Founder and Deputy CEO of Imaweb, added, “The acquisition of Stieger also supports our pan-European growth strategy by strengthening our presence in the DACH region, which is a priority market for Imaweb.”
Eugen Stieger, CEO and Founder of Stieger, said, “In Imaweb, we believe we’ve found the right partner to take Stieger forward and ensure the company’s continued success over the coming years. The Stieger team are excited to join Imaweb as the company enters the next phase of its growth.”
PSG invested in Imaweb in May 2019, backing the company’s founders to seek to transform the leading automotive CRM solutions provider in Spain into a pan-European player. Since then, Imaweb has grown quickly through a combination of organic growth and strategic M&A. This transaction is Imaweb’s third in 2021, following the acquisitions of leading German automotive digital software solutions provider Procar in January and Stampyt, a leading French AI-driven remarketing software provider, in March. Imaweb now offers a full suite of digital software solutions designed for car dealers and OEMs throughout Europe.
The financial terms of this acquisition are not being disclosed.
Imaweb
Imaweb is a leading developer and provider of digital solutions for the automotive sector in Europe. The company was formed through the merger of Imaweb, a Spanish company dedicated to developing global customer management solutions for sales, marketing and after-sales, and DATAFIRST-I’Car Systems group, a French software development company for car manufacturers, group distributers and dealers, in 2019. For more information, visit https://www.imaweb.com/ .
Stieger
Stieger Software is a leading developer of complete IT solutions and interfaces for the Swiss and Austrian automotive industries. Founded in 1982, the company now employs around 60 highly qualified people across six locations in three countries. Stieger's innovative dealer management systems are currently used by more than 1650 customers.
Stieger has a threefold core business: a cutting-edge specialty in the automotive industry, a la carte concepts and a systematic standardization policy for software use. For more information about the company, please visit https://www.stieger.ch
PSG
PSG is a growth equity firm that partners with middle-market software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 65 companies and facilitated over 275 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City and London. https://www.psgequity.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom